A Phase 1 interventional study of Quizartinib and Cytarabine in Acute Myeloid Leukemia, sponsored by Daiichi Sankyo Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by Daiichi Sankyo Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 26th largest by enrollment, is one of 4 that started in 2016, is one of 8 in phase 1, and was the 10th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Netherlands
Ages 1 mo–18 yrs
Kura Oncology, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 5
First in 2007; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 69 across the 28 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Daiichi Sankyo Co., Ltd., one of the names counted as Daiichi Sankyo. Under that name alone:
Daiichi Sankyo Co., Ltd. is the lead sponsor of 73 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.
21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo: 1 open now, 3 under way, 1 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2016, is one of 12 in phase 1, and was the 13th registered.
Daiichi Sankyo’s Leukemia, Myeloid, Acute studies by the year they started, since 1999.
1 of the studies testing quizartinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 21 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 1b, dose escalation, study of quizartinib to evaluate the safety profile, the pharmacokinetics, and the recommended dose of quizartinib for subsequent clinical studies of the combination of quizartinib and induction and consolidation chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received 20 mg quizartinib once daily in the morning under fasting conditions. For the Induction phase, cytarabine (100 mg/m\^2/day IV) and either idarubicin (12 mg/m\^2/day IV infusion) or daunorubicin (60 mg/m\^2/day IV) were co-administered with quizartinib. For the Consolidation phase, cytarabine (3.0 g/m\^2/12 hours IV) was co-administered with quizartinib.
Drug: Quizartinib · Drug: Cytarabine · Drug: Idarubicin · Drug: Daunorubicin
Participants who received 40 mg quizartinib once daily in the morning under fasting conditions. For the Induction phase, cytarabine (100 mg/m\^2/day IV) and either idarubicin (12 mg/m\^2/day IV infusion) or daunorubicin (60 mg/m\^2/day IV) were co-administered with quizartinib. For the Consolidation phase, cytarabine (3.0 g/m\^2/12 hours IV) was co-administered with quizartinib.
Drug: Quizartinib · Drug: Cytarabine · Drug: Idarubicin · Drug: Daunorubicin
\[Induction period, Cycle 1\] Once-daily repeated oral administration Day 8 to Day 21. \[Induction period, Cycle 2\] Once-daily repeated oral administration Day 6 to Day 19. \[Consolidation period\] Once-daily repeated oral administration Day 6 to Day 19.
\[Induction period, Cycle 1\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 7. \[Induction period, Cycle 2\] Once-daily intravenous injection of 100 mg/m\^2 cytarabine on Day 1 to 5. \[Consolidation period\] Twice-daily intravenous injection of 3.0 g/m\^2 cytarabine at 12-hour intervals on Days 1, 3, and 5.
Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 to 3. \[Induction period, Cycle 2\] Once-daily intravenous injection of 12 mg/m\^2 idarubicin on Day 1 and 2.
Either Idarubicin or Daunorubicin will be used \[Induction period, Cycle 1\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 to 3. \[Induction period, Cycle 2\] Once-daily intravenous injection of 60mg/m\^2 daunorubicin on Day 1 and 2.
Summary of Best Responses After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Best response was defined as the best measured complete remission (CR), CR with incomplete hematological recovery (CRi), CR with incomplete platelet recovery (CRp), Partial remission (PR), or No response (NR) in the overall response assessments at all time points after the first dose. CR is defined as absence of leukemia cells morphologically; bone marrow blasts \<5 %; neutrophil count ≥ 1000 /mm 3; platelet count ≥ 100 ,000 /mm 3, independence of RBC transfusions for 4 weeks; independence of platelet transfusions for 1 week; absence of extramedullary leukemia.
Time frame: Day 0 to Day 21 of last completed cycle (each cycle 28 days), up to approximately 1 year
Summary of Best Response Rates After the First Oral Dose of Quizartinib in Participants With Relapsed or Refractory Acute Myeloid Leukemia
Best response was defined as the best measured complete remission (CR), CR with incomplete hematological recovery (CRi), CR with incomplete platelet recovery (CRp), Partial remission (PR), or No response (NR) in the overall response assessments at all time points after the first dose.
Time frame: Day 0 to Day 21 of last completed cycle (each cycle 28 days), up to approximately 1 year
Pharmacokinetic Parameter Maximum Serum Concentration (Cmax) of Geometric Means of Quizartinib and Active Metabolite (AC886) After Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
The maximum serum plasma concentration (Cmax) is reported at Induction phase Cycle 1, Day 9 and the maximum serum plasma concentration at steady state (Cmax,ss) is reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.
Time frame: Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)
Pharmacokinetic Parameter Area Under the Concentration-Time Curve During Dosing Interval of Quizartinib and Metabolite (AC886) After Daily Dose of 20 mg or 40 mg With Chemotherapy to Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia
The area under the plasma concentration-time curve during dosing interval (AUCtau) of geometric means is reported at Induction phase Cycle 1, Day 9 and the area under the plasma concentration-time curve during dosing interval at steady state (AUCtauss) of geometric means are reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.
Time frame: Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)
Pharmacokinetic Parameter Time of Maximum Plasma Concentration (Tmax) of Quizartinib and the Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The time of maximum plasma concentration (Tmax) of geometric means is reported at Induction phase Cycle 1, Day 9 and the time of maximum plasma concentration at steady state (Tmax,ss) of geometric means is reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.
Time frame: Induction phase Cycle 1, Day 8 to Cycle 1, Day 21 (each cycle 28 days)
Pharmacokinetic Parameter Metabolite to Parent Ratio (MR) of Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The metabolite to parent ratio of geometric means for Cmax and AUCtau is reported at Induction phase Cycle 1, Day 9 for active metabolite AC886 is reported.
Time frame: Induction phase Cycle 1, Day 8 (each cycle 28 days)
Pharmacokinetic Parameter Trough Plasma Concentration (Ctrough) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The trough plasma concentration (Ctrough) of geometric means is reported at Induction phase Cycle 1, Day 21 for serum quizartinib, active metabolite AC886, and quizartinib and AC886.
Time frame: Induction phase Cycle 1, Day 21 (each cycle 28 days)
Pharmacokinetic Parameter Accumulation Ratio (AR) of Quizartinib and Active Metabolite (AC886) After a Daily Dose of 20 mg or 40 mg Combined With Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The accumulation ratio of geometric means for Cmax and AUCtau is reported at Induction phase Cycle 1, Day 21 for serum quizartinib, active metabolite AC886, and quizartinib and AC886.
Time frame: Induction phase Cycle 1, Day 21 (each cycle 28 days)
Number of Participants Treatment-Emergent Adverse Events Reported During Induction Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that emerges (or worsens) from the first dose of study drug and coadministered drugs to the follow-up visit, 35 days after the last dose of study drug and coadministered drugs, or the start date of new AML post-treatment, whichever was earlier.
Time frame: Induction phase Cycle 1, Day 1 up to 35 days after last dose in Cycle 2 (each cycle 28 days), up to approximately 1 year
Number of Participants Treatment-Emergent Adverse Events Reported During Consolidation Phase After a Daily Dose of 20 mg or 40 mg in Combination With Standard Chemotherapy to Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that emerges (or worsens) from the first dose of study drug and coadministered drugs to the follow-up visit, 35 days after the last dose of study drug and coadministered drugs, or the start date of new AML post-treatment, whichever was earlier.
Time frame: Consolidation phase Cycle 1, Day 1 up to 35 days after last dose (each cycle 28 days), up to approximately 1 year
A total of 7 participants who met all inclusion and no exclusion criteria were enrolled and received treatment in the study.
| Milestone | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Started | 4 | 3 |
| Completed | 2 | 1 |
| Not completed | 2 | 2 |
| Withdrew: Progressive disease | 0 | 1 |
| Withdrew: Cr, crp, or cri not achieved (induction cycle 2) | 2 | 0 |
| Withdrew: Relapse after cr, crp, or cri | 0 | 1 |
| Milestone | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Started | 2 | 1 |
| Completed | 1 | 0 |
| Not completed | 1 | 1 |
| Withdrew: Physician decision | 1 | 1 |
Best response was defined as the best measured complete remission (CR), CR with incomplete hematological recovery (CRi), CR with incomplete platelet recovery (CRp), Partial remission (PR), or No response (NR) in the overall response assessments at all time points after the first dose. CR is defined as absence of leukemia cells morphologically; bone marrow blasts \<5 %; neutrophil count ≥ 1000 /mm 3; platelet count ≥ 100 ,000 /mm 3, independence of RBC transfusions for 4 weeks; independence of platelet transfusions for 1 week; absence of extramedullary leukemia.
| Participants | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Complete remission (CR) | 0 | 0 |
| CR with incomplete platelet recovery (CRp) | 0 | 0 |
| CR with incomplete hematological recovery (CRi) | 3 | 2 |
| Partial remission (PR) | 1 | 0 |
| No response (NR) | 0 | 1 |
Best response was defined as the best measured complete remission (CR), CR with incomplete hematological recovery (CRi), CR with incomplete platelet recovery (CRp), Partial remission (PR), or No response (NR) in the overall response assessments at all time points after the first dose.
| percentage of participants | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Composite CR rate (CRc rate: CR+CRp+CRi) | 75.0 (30.1 to 95.4) | 66.7 (20.8 to 93.9) |
| Response rate (CRc+PR) | 100 (51.0 to 100.0) | 66.7 (20.8 to 93.9) |
The maximum serum plasma concentration (Cmax) is reported at Induction phase Cycle 1, Day 9 and the maximum serum plasma concentration at steady state (Cmax,ss) is reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.
| ng/mL | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Cycle 1, Day 8: Quizartinib, Cmax | 42.4 ± 25.7 | 91.3 ± 28.5 |
| Cycle 1, Day 8: AC886, Cmax | 36.5 ± 25.4 | 103 ± 37.0 |
| Cycle 1, Day 8: Quizartinib + AC886, Cmax | 77.4 ± 10.3 | 180 ± 16.0 |
| Cycle 1, Day 21: Quizartinib, Cmax, ss | 64.2 ± 64.0 | 212 ± 47.4 |
| Cycle 1, Day 21: AC886, Cmax, ss | 96.7 ± 23.7 | 256 ± 45.0 |
| Cycle 1, Day 21: Quizartinib + AC886, Cmax | 162 ± 35.3 | 480 ± 2.4 |
The area under the plasma concentration-time curve during dosing interval (AUCtau) of geometric means is reported at Induction phase Cycle 1, Day 9 and the area under the plasma concentration-time curve during dosing interval at steady state (AUCtauss) of geometric means are reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.
| ng*h/mL | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Cycle 1, Day 8: Quizartinib, AUCtau | 418 ± 50.4 | 921 ± 31.3 |
| Cycle 1, Day 8: AC886, AUCtau | 555 ± 28.8 | 1640 ± 24.4 |
| Cycle 1, Day 8: Quizartinib + AC886, AUCtau | 1010 ± 26.9 | 2640 ± 8.0 |
| Cycle 1, Day 21: Quizartinib, AUCtau,ss | 991 ± 87.7 | 2940 ± 76.6 |
| Cycle 1, Day 21: AC886, AUCtau, ss | 1940 ± 25.4 | 5310 ± 40.6 |
| Cycle 1, Day 21: Quizartinib + AC886, AUCtau | 3020 ± 42.3 | 8850 ± 0.3 |
The time of maximum plasma concentration (Tmax) of geometric means is reported at Induction phase Cycle 1, Day 9 and the time of maximum plasma concentration at steady state (Tmax,ss) of geometric means is reported at Induction phase Cycle 1, Day 21 for quizartinib, active metabolite AC886, and quizartinib and AC886.
| hour | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Cycle 1, Day 8: Quizartinib, Tmax | 3.03 (1.05 to 6.03) | 2.17 (2.07 to 4.17) |
| Cycle 1, Day 8: AC886, Tmax | 5.01 (2.05 to 6.03) | 6.08 (4.03 to 6.17) |
| Cycle 1, Day 8: Quizartinib + AC886, Tmax | 4.01 (2.05 to 6.03) | 4.17 (4.03 to 6.17) |
| Cycle 1, Day 21: Quizartinib, Tmax,ss | 4.03 (2.03 to 4.13) | 4.08 (4.05 to 4.12) |
| Cycle 1, Day 21: AC886, Tmax,ss | 5.02 (2.08 to 5.98) | 6.09 (6.05 to 6.13) |
| Cycle 1, Day 21: Quizartinib + AC886, Tmax | 4.03 (2.08 to 5.93) | 4.08 (4.05 to 4.12) |
The metabolite to parent ratio of geometric means for Cmax and AUCtau is reported at Induction phase Cycle 1, Day 9 for active metabolite AC886 is reported.
| metabolite to parent ratio | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Cycle 1, Day 8: MR (Cmax) | 0.861 ± 43.8 | 1.13 ± 45.6 |
| Cycle 1, Day 8: MR (AUCtau) | 1.33 ± 64.1 | 1.78 ± 56.4 |
The trough plasma concentration (Ctrough) of geometric means is reported at Induction phase Cycle 1, Day 21 for serum quizartinib, active metabolite AC886, and quizartinib and AC886.
| ng/mL | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Cycle 1, Day 21: Quizartinib | 22.7 ± 173.4 | 77.1 ± 117.6 |
| Cycle 1, Day 21: AC886 | 68.6 ± 49.3 | 195 ± 46.1 |
| Cycle 1, Day 21: Quizartinib + AC886 | 94.6 ± 68.5 | 299 ± 3.3 |
The accumulation ratio of geometric means for Cmax and AUCtau is reported at Induction phase Cycle 1, Day 21 for serum quizartinib, active metabolite AC886, and quizartinib and AC886.
| accumulation ratio | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Cycle 1, Day 21: Quizartinib AR (Cmax) | 1.52 ± 72.1 | 1.98 ± 58.5 |
| Cycle 1, Day 21: AC886 AR (Cmax) | 2.65 ± 46.9 | 2.55 ± 7.2 |
| Cycle 1, Day 21: Quizartinib + AC886 AR (Cmax) | 2.09 ± 41.6 | 2.53 ± 16.2 |
| Cycle 1, Day 21: Quizartinib AR (AUCtau) | 2.37 ± 88.5 | 2.84 ± 36.2 |
| Cycle 1, Day 21: AC886 AR (AUCtau) | 3.50 ± 56.2 | 3.31 ± 5.4 |
| Cycle 1, Day 21: Quizartinib + AC886 AR (AUCtau) | 2.99 ± 59.5 | 3.24 ± 6.8 |
A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that emerges (or worsens) from the first dose of study drug and coadministered drugs to the follow-up visit, 35 days after the last dose of study drug and coadministered drugs, or the start date of new AML post-treatment, whichever was earlier.
| Participants | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Participants with TEAEs | 4 | 3 |
| Infections and Infestations | 1 | 3 |
| Pneumonia | 1 | 1 |
| Skin infection | 0 | 1 |
| Staphylococcal bacteraemia | 0 | 1 |
| Blood and Lymphatic System Disorders | 4 | 3 |
| Febrile neutropenia | 4 | 3 |
| Anaemia | 2 | 1 |
| Leukopenia | 1 | 0 |
| Neutropenia | 1 | 0 |
| Thrombocytopenia | 1 | 0 |
| Immune Disorders | 0 | 1 |
| Hypersensitivity | 0 | 1 |
| Metabolism and Nutrition Disorders | 3 | 2 |
| Decreased appetite | 3 | 1 |
| Hypoalbuminaemia | 1 | 1 |
| Hypokalaemia | 2 | 0 |
| Hypomagnesaemia | 1 | 0 |
| Hyponatraemia | 1 | 0 |
| Hypophosphataemia | 1 | 0 |
| Hypouricaemia | 0 | 1 |
| Tumour lysis syndrome | 1 | 0 |
| Nervous System Disorders | 2 | 1 |
| Dysgeusia | 2 | 1 |
| Dizziness | 1 | 0 |
| Eye Disorders | 1 | 0 |
| Photophobia | 1 | 0 |
| Cardiac Disorders | 0 | 1 |
| Palpitations | 0 | 1 |
| Vascular Disorders | 0 | 1 |
| Hypotension | 0 | 1 |
| Respiratory, Thoracic, and Mediastinal Disorders | 0 | 1 |
| Epistaxis | 0 | 1 |
| Oropharyngeal pain | 0 | 1 |
| Respiratory disorder | 0 | 1 |
| Gastrointestinal Disorders | 3 | 3 |
| Abdominal pain upper | 3 | 1 |
| Nausea | 2 | 2 |
| Constipation | 1 | 2 |
| Diarrhoea | 1 | 2 |
| Stomatitis | 2 | 1 |
| Cheilitis | 1 | 1 |
| Vomiting | 1 | 1 |
| Melaena | 0 | 1 |
| Hepatobiliary Disorders | 0 | 1 |
| Hepatic function abnormal | 0 | 1 |
| Skin and Subcutaneous Tissue Disorders | 4 | 3 |
| Alopecia | 3 | 2 |
| Rash | 1 | 2 |
| Rash maculo-papular | 1 | 1 |
| Dermatitis bullous | 0 | 1 |
| Dry skin | 0 | 1 |
| Musculoskeletal and Connective Tissue Disorders | 1 | 3 |
| Arthralgia | 0 | 2 |
| Musculoskeletal pain | 0 | 1 |
| Myalgia | 1 | 0 |
| Pain in extremity | 0 | 1 |
| Renal and Urinary Disorders | 1 | 0 |
| Haematuria | 1 | 0 |
| Proteinuria | 1 | 0 |
| Urinary tract pain | 1 | 0 |
| Reproductive System and Breast Disorders | 0 | 1 |
| Menorrhagia | 0 | 1 |
| General Disorders & Administration Site Conditions | 0 | 1 |
| Oedema peripheral | 0 | 1 |
| Pyrexia | 0 | 1 |
| Investigations | 4 | 3 |
| Gamma-glutamyltransferase increased | 3 | 1 |
| Alanine aminotransferase increased | 2 | 1 |
| Blood alkaline phosphatase increased | 1 | 1 |
| Electrocardiogram QT prolonged | 0 | 2 |
| Platelet count decreased | 1 | 1 |
| Weight decreased | 1 | 1 |
| White blood cell count decreased | 1 | 1 |
| Aspartate aminotransferase | 1 | 0 |
| Aspartate aminotransferase increased | 0 | 1 |
| Blood bilirubin increased | 1 | 0 |
| Blood lactate dehydrogenase increased | 0 | 1 |
| Blood pressure decreased | 0 | 1 |
| Lipase increased | 0 | 1 |
A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE) that emerges (or worsens) from the first dose of study drug and coadministered drugs to the follow-up visit, 35 days after the last dose of study drug and coadministered drugs, or the start date of new AML post-treatment, whichever was earlier.
| Participants | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Participants with TEAEs | 2 | 1 |
| Infections and Infestations | 1 | 1 |
| Lung infection | 0 | 1 |
| Skin infection | 1 | 0 |
| Upper respiratory tract infection | 1 | 0 |
| Blood and Lymphatic System Disorders | 2 | 1 |
| Febrile neutropenia | 2 | 1 |
| Nervous System Disorders | 1 | 0 |
| Dysgeusia | 1 | 0 |
| Gastrointestinal Disorders | 2 | 0 |
| Diarrhoea | 2 | 0 |
| Nausea | 1 | 0 |
| Stomatitis | 1 | 0 |
| Skin and Subcutaneous Tissue Disorders | 1 | 1 |
| Rash | 1 | 0 |
| Rash maculo-papular | 0 | 1 |
| General Disorders & Administration Site Conditions | 1 | 0 |
| Oedema peripheral | 1 | 0 |
| Investigations | 2 | 1 |
| Platelet count decreased | 1 | 1 |
| White blood cell count decreased | 1 | 1 |
| Alanine aminotransferase increased | 1 | 0 |
| Electrocardiogram QT prolonged | 0 | 1 |
| Injury, Poisoning, and Procedural Complications | 0 | 1 |
| Contusion | 0 | 1 |
| Fall | 0 | 1 |
Collected over Adverse events (AEs) were collected from Induction phase Cycle 1, Day 1 up to 35 days after last completed cycle in Consolidation phase, up to approximately 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Quizartinib 20 mg/Day | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Quizartinib 40 mg/Day | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Event | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| PneumoniaInfections and infestations | 0/4 | 1/3 |
| Staphylococcal bacteraemiaInfections and infestations | 0/4 | 1/3 |
| Event | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 4/4 | 3/3 |
| Electrocardiogram QT prolongedInvestigations | 0/4 | 3/3 |
| Decreased appetiteMetabolism and nutrition disorders | 3/4 | 1/3 |
| DysgeusiaNervous system disorders | 3/4 | 1/3 |
| DiarrhoeaGastrointestinal disorders | 3/4 | 2/3 |
| NauseaGastrointestinal disorders | 3/4 | 2/3 |
| Abdominal pain upperGastrointestinal disorders | 3/4 | 1/3 |
| StomatitisGastrointestinal disorders | 3/4 | 1/3 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/4 | 2/3 |
| Gamma-glutamyltransferase increasedInvestigations | 3/4 | 1/3 |
| Age, Categorical(Participants) | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 2 | 4 |
| >=65 years | 2 | 1 | 3 |
| Age, Continuous(years) | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day | Total |
|---|---|---|---|
| Mean | 57.5 ± 10.5 | 53.7 ± 17.1 | 55.9 ± 12.5 |
| Sex: Female, Male(Participants) | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Quizartinib 20 mg/Day | Quizartinib 40 mg/Day | Total |
|---|---|---|---|
| Japan | 4 | 3 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Aug 2016 to primary completion in Oct 2017, 14 months.
Results were first posted in Aug 2021, 3 years 10 months after primary completion.
Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 14 months is below that.
Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Quizartinib